- Markets
- Healthcare
- GENNEX
GENNEX
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Gennex Laboratories Says Unit Got Andhra Pradesh Government Approval To Manufacture Additional Products
Oct 28 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT ANDHRA PRADESH GOVERNMENT APPROVAL TO MANUFACTURE ADDITIONAL PRODUCTS
Source text: ID:nBSE5F4rKr
Further company coverage: GNXL.BO
(([email protected];;))
Oct 28 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT ANDHRA PRADESH GOVERNMENT APPROVAL TO MANUFACTURE ADDITIONAL PRODUCTS
Source text: ID:nBSE5F4rKr
Further company coverage: GNXL.BO
(([email protected];;))
Gennex Laboratories To Consider Fundraising By Way Of Preferential Issue
Nov 29 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER FUNDRAISING BY WAY OF PREFERENTIAL ISSUE
Source text for Eikon: ID:nBSE4ndZ58
Further company coverage: GNXL.BO
(([email protected];))
Nov 29 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER FUNDRAISING BY WAY OF PREFERENTIAL ISSUE
Source text for Eikon: ID:nBSE4ndZ58
Further company coverage: GNXL.BO
(([email protected];))
Gennex Laboratories To Consider Preferential Issue Of Shares
Nov 20 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER PREFERENTIAL ISSUE OF SHARES TO SPECIFIC INDIVIDUALS AND ENTITIES
Source text for Eikon: ID:nBSEc4W2wz
Further company coverage: GNXL.BO
(([email protected];;))
Nov 20 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER PREFERENTIAL ISSUE OF SHARES TO SPECIFIC INDIVIDUALS AND ENTITIES
Source text for Eikon: ID:nBSEc4W2wz
Further company coverage: GNXL.BO
(([email protected];;))
Gennex Laboratories Unit Received License From Government Of Andhra Pradesh
June 1 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT RECEIVED LICENSE TO MANUFACTURE FOR SALE OF DRUGS FROM GOV OF ANDHRA PRADESH
Source text for Eikon: ID:nBSE4By8Zr
Further company coverage: GNXL.BO
(([email protected];))
June 1 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT RECEIVED LICENSE TO MANUFACTURE FOR SALE OF DRUGS FROM GOV OF ANDHRA PRADESH
Source text for Eikon: ID:nBSE4By8Zr
Further company coverage: GNXL.BO
(([email protected];))
Gennex Laboratories Unit Got CFO Approval From Pollution Control Board
May 31 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT CFO APPROVAL FROM POLLUTION CONTROL BOARD
Source text for Eikon: ID:nBSE5JbWx6
Further company coverage: GNXL.BO
(([email protected];))
May 31 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT CFO APPROVAL FROM POLLUTION CONTROL BOARD
Source text for Eikon: ID:nBSE5JbWx6
Further company coverage: GNXL.BO
(([email protected];))
Events:
Rights
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Gennex Lab do?
Gennex Laboratories Ltd specializes in the production and export of bulk drugs and intermediates such as Guaiphenesin, Methocarbamol, Fluconazole, and Phenazopyridine.
Who are the competitors of Gennex Lab?
Gennex Lab major competitors are Trident Lifeline, Fredun Pharma, Ambalal Sarabhai Ent, Balaxi Pharma., Coral Laboratories, Alpa Lab, Lyka Labs. Market Cap of Gennex Lab is ₹315 Crs. While the median market cap of its peers are ₹310 Crs.
Is Gennex Lab financially stable compared to its competitors?
Gennex Lab seems to be less financially stable compared to its competitors. Altman Z score of Gennex Lab is 5.22 and is ranked 5 out of its 8 competitors.
Does Gennex Lab pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Gennex Lab latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Gennex Lab allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Short Term Loans & Advances
How strong is Gennex Lab balance sheet?
Balance sheet of Gennex Lab is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Gennex Lab improving?
Yes, profit is increasing. The profit of Gennex Lab is ₹19.59 Crs for TTM, ₹11.37 Crs for Mar 2024 and ₹6.19 Crs for Mar 2023.
Is the debt of Gennex Lab increasing or decreasing?
Yes, The debt of Gennex Lab is increasing. Latest debt of Gennex Lab is -₹23.21 Crs as of Sep-24. This is greater than Mar-24 when it was -₹94.99 Crs.
Is Gennex Lab stock expensive?
Gennex Lab is not expensive. Latest PE of Gennex Lab is 16.91, while 3 year average PE is 30.73. Also latest EV/EBITDA of Gennex Lab is 12.64 while 3yr average is 18.24.
Has the share price of Gennex Lab grown faster than its competition?
Gennex Lab has given better returns compared to its competitors. Gennex Lab has grown at ~53.64% over the last 2yrs while peers have grown at a median rate of 33.28%
Is the promoter bullish about Gennex Lab?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Gennex Lab is 18.42% and last quarter promoter holding is 18.42%.
Are mutual funds buying/selling Gennex Lab?
There is Insufficient data to gauge this.